According to recent report, the Danish pharmaceutical group Novo Nordisk foresees large growth in the insulin market in Russia, mirroring what has happened in China in recent years.
Novo, who have hit diabetes headlines recently due to their pledge to help children in developing countries manage type 1 diabetes, foresee major expansion into the Russian market in the next few years.
More and more people are being diagnosed with type 2 diabetes in Russia. Novo Chief Executive Lars Sorenson reportedly commented: "We expect growth rates in Russia of over 20 percent for a number of years into the future."
According to Russian Diabetes Federation estimates, as many as 10 million people will be diagnosed with diabetes in Russia by 2025.
Diabetes company sees potential in Russia
Fri, 30 Jan 2009
Recommended links
Diabetes newsletterDiabetes financial services
Diabetes forum and community
Diabetes guides
Diabetes support forums
Diabetes pill could see end of injections
Major diabetes risk amongst Maoris
Diabetes company foresee device growth
Company files for diabetes drug application
Company sets up diabetes research fund
Company sponsors diabetes day
Diabetes drug company say efficiency is proven
Diabetes company get Canadian approval
Diabetes drug company trial hitch
Pfizer in major bid for drug company
Diabetes Company says new drug is efficient
Diabetes company shares hit a low
Diabetes test patent given to company
Diabetes drug company shares climb
New company in type 2 diabetes development
Diabetes company faces further controversy
Diabetes drug company sales fall
Company gets boost in diabetes battle
Diabetes Drug Company losing less
Diabetes company looking for drug approval
Diabetes drug company call for approval
Drug company will continue diabetes trial
Diabetes company profits continue to climb
Join us